Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy

NCT04408924 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04408924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04408924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
January 20, 2021
Completion date
June 2, 2023
Enrollment
44 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer